No connection

Search Results

CCM

BEARISH
$4.0 Live
Concord Medical Services Holdings Limited · NYSE
$3.18 52W Range $10.77

At a glance

Key valuation, profitability, growth, and risk metrics.

Updated Apr 25, 2026
Market cap
$17.37M
P/E
N/A
ROE
-29.0%
Profit margin
-44.6%
Debt/Equity
2.22
Dividend yield
N/A

AI Analysis

AI-powered fundamental assessment

Confidence
95%
CCM exhibits severe financial distress, anchored by a weak Piotroski F-Score of 3/9 and a critical liquidity crisis. The company suffers from negative gross margins (-11.44%), meaning it loses money on every unit of service provided before operating expenses are even considered. With a Price-to-Book ratio of -0.05, the company has negative shareholder equity, and a Quick Ratio of 0.10 indicates an inability to meet short-term obligations. Combined with declining revenue (-8.30% YoY) and a 5-year price collapse of 89%, the fundamental outlook is highly precarious.

Key Strengths

Extremely low Price-to-Sales ratio (0.05)
Recent short-term price recovery (+9.6% over 1 month)
Positive Q/Q EPS growth (+60.4%) though still negative in absolute terms
Micro-cap size allows for high volatility spikes
Operating in the essential Healthcare sector

Key Risks

Negative Gross Margins indicating a fundamentally broken business model
Severe liquidity risk with a Current Ratio of 0.42 and Quick Ratio of 0.10
Negative Book Value (Price/Book -0.05) suggesting insolvency
Consistent history of massive earnings misses (Average surprise -445.51%)
Declining top-line revenue growth (-8.30% YoY)

Performance Snowflake

Multi-dimensional analysis across 5 key categories

Overall
10
Weak
Value
10
Future
20
Past
15
Health
5
Dividend
0
AI Verdict
Distressed / High Bankruptcy Risk
Key drivers: Negative Equity, Negative Gross Margins, Liquidity Crisis, Revenue Decline
Confidence
90%
Value
10/100

Valuation metrics are largely irrelevant as the company is operating with negative equity.

Positives
  • Low P/S ratio
Watchpoints
  • Negative P/B ratio
  • Negative Forward P/E
  • No Graham Number possible due to negative earnings/book value
Future
20/100

Growth metrics are negative or insufficient to offset operational losses.

Positives
  • Recent Q/Q EPS improvement
Watchpoints
  • Negative YoY Revenue growth
  • Negative operating margins (-72.10%)
Past
15/100

Long-term trend is a steady decline from a previously profitable state.

Positives
  • Historical periods of profitability (2011-2015)
Watchpoints
  • 5-year price decline of 89%
  • Consistent earnings misses over the last 4 quarters
Health
5/100

Critical failure in liquidity and solvency metrics.

Positives
No standout positives identified.
Watchpoints
  • Piotroski F-Score 3/9 (Weak)
  • Current Ratio 0.42
  • Quick Ratio 0.10
  • Debt/Equity 2.22
Dividend
0/100

Dividend strength is 0/100.

Positives
No standout positives identified.
Watchpoints
  • No dividend paid
  • No capacity for dividends given negative margins

Stock Price & Analyst Targets

Real-time price movements and analyst price targets

Current Price
$4.0

Multi-Horizon Performance vs Peers

Price momentum across 5Y → 1W horizons for CCM and closest competitors.

Updated 2026-04-24
CCM
Concord Medical Services Holdings Limited
Primary
5Y
-89.0%
3Y
-71.8%
1Y
-12.3%
6M
-21.4%
1M
+9.6%
1W
+1.8%
LPC
Lipocine Inc.
Peer
5Y
-90.5%
3Y
-50.9%
1Y
-23.7%
6M
-23.5%
1M
-67.6%
1W
+22.7%
ZJY
Jin Medical International Ltd.
Peer
5Y
-72.9%
3Y
-71.2%
1Y
-87.7%
6M
-68.8%
1M
+11.1%
1W
+7.2%
OSR
OSR Holdings, Inc.
Peer
5Y
-94.6%
3Y
-94.6%
1Y
-62.3%
6M
-8.9%
1M
+21.5%
1W
+11.1%
CUE
Cue Biopharma, Inc.
Peer
5Y
-98.5%
3Y
-94.2%
1Y
-69.9%
6M
-75.0%
1M
-37.5%
1W
-18.2%

Positive values indicate cumulative gains over the specified period. Comparables pulled from the same sector to highlight whether momentum is stock-specific or industry-wide.

Historical Performance Trends

Long-term financial metrics and growth patterns

Revenue & Net Income

Profit & Operating Margins

Return on Equity (ROE)

Quarterly Revenue Growth

Historical data shows last 12 quarters (3 years)

Valuation Metrics

Key valuation ratios and pricing indicators

P/E Ratio
N/A
Forward P/E
-26.67
PEG Ratio
0.56
P/B Ratio
-0.05
P/S Ratio
0.05
EV/Revenue
22.23
EV/EBITDA
-22.79
Market Cap
$17.37M

Profitability

Profit margins and return metrics

Profit Margin -44.6%
Operating Margin -72.1%
Gross Margin -11.44%
ROE -29.03%
ROA -4.48%

Growth

Revenue and earnings growth rates

Revenue Growth -8.3%
Earnings Growth N/A
Q/Q Revenue Growth N/A
Q/Q Earnings Growth N/A

Financial Health

Balance sheet strength and liquidity metrics

Debt/Equity
2.22
High debt
Current Ratio
0.42
Weak
Quick Ratio
0.1
Poor
Cash/Share
$1.35

Financial Statement Flow

Interactive flow visualization showing how money moves through the company Q2 2025

Total Assets
$6.7B
Liabilities
$5.0B
Equity
$-2.2B
Debt/Equity
-2.24x

Quarterly Earnings History

EPS performance vs analyst estimates

2020-04-29
$-1.7
-136.0% surprise
2019-08-22
$-4.29
-1548.1% surprise
2019-04-29
$-1.02
+68.0% surprise
2019-04-29
$-1.78
-165.9% surprise

Healthcare Sector Comparison

Comparing CCM against 536 companies in the Healthcare sector (28 bullish, 158 neutral, 350 bearish)
Return on Equity (ROE)
-29.03%
This Stock
vs
-92.06%
Sector Avg
-68.5% (Below Avg)
Profit Margin
-44.6%
This Stock
vs
-16.51%
Sector Avg
+170.1% (Superior)
Debt to Equity
2.22
This Stock
vs
2.73
Sector Avg
-18.8% (Lower)
Revenue Growth
-8.3%
This Stock
vs
129.68%
Sector Avg
-106.4% (Slower)
Current Ratio
0.42
This Stock
vs
4.57
Sector Avg
-90.9% (Weaker)

Similar Companies

Peer comparison within the same industry

SEC Filings

Recent regulatory filings from the SEC EDGAR database

20-F
20-F
2025-04-25

CCM filed its annual report on Form 20-F on April 25, 2025. This filing provides the comprehensive annual financial disclosures and risk assessments required for foreign private issuers.

Data sourced from SEC EDGAR. AI summaries generated automatically.

Past News Coverage

Recent headlines mentioning CCM from our newsroom.

Newest → oldest
TradingGPT V2 Copilot
Fundamentals • Valuation • Risk
Hi! I'm your fundamentals copilot.

Ask me to:
• Summarize the business quality
• Review valuation and multiples
• Highlight risks and red flags
• Explain growth and margin trends
Home
Terminal
AI Chat
Markets
Profile